title: [The normalized smoothness index and parametric population RDH index of telmisartane in patients with newly diagnosed hypertension and metabolic syndrome].
abstract: BACKGROUND
  Ambulatory blood pressure monitoring provides an opportunity to evaluate 24-hour efficacy of once daily preparations.
  
  
  OBJECTIVE
  To evaluate 24-hour efficacy of telmisartane in patients with newly diagnosed hypertension and metabolic syndrome using the parametric population RDH index and normalized smoothness index.
  
  
  METHODS
  Thirty newly diagnosed hypertonics with metabolic syndrome, sufficiently responding to blood pressure therapy with telmisartane, assessed using sphygmomanometer. Twenty six men, 4 women, mean age of 44 years, body mass index of 31.4 kg. m2, before and after 1 year of therapy. Blood pressure measured with sphygmomanometer and 24-hour ambulatory monitoring (SpaceLabs 90207) according to the criteria of the European Society of Hypertension. Hypertension was defined as sphygmomanometer-measured blood pressure values of more or equal to 130 and/or 85 mm Hg. Fulfilment of at least 3 criteria of metabolic syndrome according to the definition by The Adult Treatment Panel III.
  
  
  RESULTS
  The population normalized smoothness index oftelmisartane (+/- standard error of the mean) of 1.00 +/- 0.11 for systolic pressure and 0.84 +/- 0.10 for diastolic pressure. The parametric population RDH index of 24, 24, 0 for systolic pressure and 22, 15, 1 for diastolic pressure.
  
  
  CONCLUSIONS
  Telmisartane at a mean dose of 60 mg once daily showed an adequate 24-hour efficacy in patients with newly diagnosed hypertension and metabolic syndrome responding to treatment, when blood pressure was measured using sphygmomanometer and the effect expressed as the parametric population RDH index and normalized smoothness index based on systolic blood pressure value. We did not prove the full 24-hour efficacy when diastolic blood pressure was used to calculate both indexes.
authors.affiliation: II. interní klinika Lékarské fakulty MU a FN u sv. Anny Brno. ivan.rihacek@fnusa.cz
authors.forename: I
authors.initials: I
authors.lastname: Rihácek
authors.forename: P
authors.initials: P
authors.lastname: Frána
authors.forename: D
authors.initials: D
authors.lastname: Schwarz
authors.forename: M
authors.initials: M
authors.lastname: Plachý
authors.forename: M
authors.initials: M
authors.lastname: Soucek
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D000077333:Telmisartan
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan